Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Tenax Therapeutics, Inc. (TENX) had Normalized Income after Taxes of $-10.41M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-10.41M |
|
-- |
|
-- |
|
$11.34M |
|
$-11.34M |
|
$0.93M |
|
$-10.41M |
|
$-10.41M |
|
$-10.41M |
|
$-10.41M |
|
$-10.41M |
|
|
Normalized Income after Taxes |
$-10.41M |
$-11.34M |
|
$-11.34M |
|
36.59M |
|
36.59M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$112.06M |
|
-- |
|
-- |
|
$112.06M |
|
$2.77M |
|
-- |
|
-- |
|
$2.77M |
|
$109.29M |
|
$109.29M |
|
$109.29M |
|
3.97M |
|
| Cash Flow Statement Financials | |
$-6.97M |
|
-- |
|
$23.56M |
|
$94.85M |
|
$111.45M |
|
$16.60M |
|
$4.14M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
40.48 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-6.97M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.52% |
|
-9.52% |
|
-9.29% |
|
-9.52% |
|
$27.53 |
|
$-0.19 |
|
$-0.19 |
|